Patent for Copaxone ceased in 2014 , but pesumbaly the two companies are working together as NSB would need to source Copaxone part of the product or the news story attached (dated 2018) might also explain https://www.fiercepharma.com/pharma/facing-generics-from-mylan-and-novartis-teva-loses-patent-appeal-copaxone "Teva's patent failure gives long-acting Copaxone generics free rein"
Ann: NSB files new patent, page-13
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
